Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A human airway-on-a-chip microphysiological system for modeling chlorine gas toxicity.

Toxicological sciences : an official journal of the Society of Toxicology·2025
Same author

Urinary symptoms and female sexual dysfunction in women with type 1 diabetes: the role of depression.

The journal of sexual medicine·2023
Same author

Critical Analysis of Apixaban Dose Adjustment Criteria.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2021
Same author

Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2019
Same author

Blood pressure, antihypertensive medication use, and risk of erectile dysfunction in men with type I diabetes.

Journal of hypertension·2019
Same author

Predictors of anticoagulation quality in 15 834 patients performing patient self-management of oral anticoagulation with vitamin K antagonists in real-life practice: a survey of the International Self-Monitoring Association of Orally Anticoagulated Patients.

British journal of haematology·2016

Related Experiment Video

Updated: May 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Is there a role for warfarin anymore?

Alan Jacobson1

  • 1Veterans Administration Healthcare System, Loma Linda, CA 92357, USA. alan.jacobson@va.gov

Hematology. American Society of Hematology. Education Program
|December 13, 2012
PubMed
Summary

New anticoagulant drugs offer advantages over warfarin for stroke risk reduction, but careful patient monitoring is still essential for safe and effective use in clinical practice.

Area of Science:

  • Cardiology
  • Pharmacology
  • Neurology

Background:

  • Warfarin is a leading anticoagulant for atrial fibrillation-associated stroke risk, requiring complex management.
  • Novel anticoagulant agents demonstrate comparable or superior efficacy and safety to warfarin in clinical trials.
  • These newer agents offer benefits like fixed dosing and reduced intracranial hemorrhage risk.

Purpose of the Study:

  • To evaluate the advantages and disadvantages of novel anticoagulant agents compared to warfarin.
  • To assess the implications of these new agents for clinical practice and patient outcomes.
  • To determine the conditions under which novel anticoagulants may replace warfarin.

Main Methods:

  • Review of clinical trial data comparing novel anticoagulants with warfarin.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: May 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

  • Analysis of efficacy, safety, adherence, and management requirements.
  • Consideration of potential benefits and risks in routine clinical settings.

    • Main Results:

    • Novel anticoagulants show comparable or superior effectiveness and safety to warfarin.
    • These agents do not require routine laboratory monitoring for anticoagulation.
    • Hemorrhagic risk is similar to warfarin, necessitating ongoing patient assessment.

    Conclusions:

    • Novel anticoagulants represent a significant advancement in thromboembolic disease management.
    • Despite advantages, careful patient education and follow-up are crucial for safe use.
    • Further understanding of real-world application is needed to establish their role relative to warfarin.